Minnie Kuo - 20 Jan 2026 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Role
Chief Operating Officer
Signature
/s/ Jennifer Woo, attorney-in-fact
Issuer symbol
PLRX
Transactions as of
20 Jan 2026
Net transactions value
-$8,854
Form type
4
Filing time
22 Jan 2026, 21:38:28 UTC
Previous filing
22 Dec 2025
Next filing
26 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kuo Minnie Chief Operating Officer C/O PLIANT THERAPEUTICS, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO /s/ Jennifer Woo, attorney-in-fact 22 Jan 2026 0002101360

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLRX Common Stock Sale $8,854 -6,917 -15% $1.28 37,806 20 Jan 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.